Abstract
Hypofunction of the serotonin (5-HT) 5-HT2C receptor (5-HT2CR) has been implicated in a variety of disorders including substance use disorders. As such, approaches to enhance 5-HT2CR signaling display therapeutic potential. In the present study, we show that disruption of the 5-HT2CR interaction with the protein phosphatase and tensin homolog (PTEN) via peptidomimetic-based protein-protein interaction disrupters enhances 5-HT2CR-mediating signaling in vitro and potentiates selective 5-HT2CR agonists in behavioral rodent models. Overall, the present study provides further evidence that 5-HT2CR activity can be modulated through an allosteric protein-protein interaction. This work provides the groundwork for the continued exploration of protein-protein interactions that can allosterically modulate this critical receptor and other important GPCRs for new therapeutic development through mechanisms that may display clinical utility.
| Original language | English (US) |
|---|---|
| Article number | 907 |
| Journal | Frontiers in Pharmacology |
| Volume | 10 |
| Issue number | JULY |
| DOIs | |
| State | Published - 2019 |
Keywords
- Drug discrimination
- Peptidomimetics
- Protein phosphatase and tensin homolog
- Protein-protein interactions
- Serotonin 2C receptor
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Fingerprint
Dive into the research topics of 'In vivo and in vitro analyses of novel peptidomimetic disruptors for the serotonin 5-HT2C receptor interaction with phosphatase and tensin homolog (PTEN)'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS